TENAX THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $77.32M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 31, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 10, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | After market close | – | $-0.27 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 25, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | – | $0.19 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | Before market open | – | – | – |
Press releases
Announcements Tenax Therapeutics filed with the SEC
LEVEL Clinical Trial Results September
Regulation FD disclosure · EX-99.1 to Form 8-K
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
Other events · EX-99.1 to Form 8-K
LEVEL Clinical Trial Topline Results
Other events · EX-99.2 to Form 8-K
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
Other events · EX-99.1 to Form 8-K
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
Other events · EX-99.1 to Form 8-K
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
Other events · EX-99.1 to Form 8-K
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Tenax Therapeutics Announces $25 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
Regulation FD disclosure · EX-99.1 to Form 8-K
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Tenax Therapeutics Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Tenax Therapeutics Provides 2023 Business Update
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Tenax Therapeutics Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Tenax Therapeutics Announces the Evaluation of Strategic Alternatives
Other events · EX-99.1 to Form 8-K
Comparative Pharmacokinetic Study of TNX-201
Other events · EX-99.1 to Form 8-K